Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database
A high proportion of GBM patients in the United States undergo MGMT promoter testing, though significant sociodemographic disparities exist. While there was a decrease in chemoradiotherapy use with increasing age, radiotherapy alone was more commonly administered to elderly patients than chemotherapy alone irrespective of MGMT promoter methylation status.
Authors
- Frank J. Attenello (ORCID: https://orcid.org/0000-0002-7218-8669)
- David J. Coté (ORCID: https://orcid.org/0000-0001-5419-1517)
- Frances Chow (ORCID: https://orcid.org/0000-0001-5402-2473)
- John Pham (ORCID: https://orcid.org/0000-0003-2762-9047)
- Apurva Prasad
- Robert G. Briggs (ORCID: https://orcid.org/0000-0001-9329-4471)
- Jonathan Sisti (ORCID: https://orcid.org/0000-0001-9011-1668)
- Gabriel Zada (ORCID: https://orcid.org/0000-0001-5821-902X)
- Keiko M. Kang
- David Gómez (ORCID: https://orcid.org/0000-0003-3612-661X)
- Clark C. Chen (ORCID: https://orcid.org/0000-0001-6258-9277)
- Sindhu Daggupati
Institutions
- University of Southern California (US)
- Brown University (US)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1007/s11060-025-04952-y
- Citations
- 10
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 16.25
Funders
- University of Southern California